Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus
Open Access
- 1 January 2009
- journal article
- Published by Portico in Human Genomics and Proteomics
- Vol. 1 (1)
- https://doi.org/10.4061/2009/374312
Abstract
To identify potential pharmacodynamic biomarkers to guide dose selection in clinical trials using anti-interferon-alpha (IFN-α) monoclonal antibody (mAb) therapy for systemic lupus erythematosus (SLE), we used an Affymetrix human genome array platform and identified 110 IFN-α/β-inducible transcripts significantly upregulated in whole blood (WB) of 41 SLE patients. The overexpression of these genes was confirmed prospectively in 54 additional SLE patients and allowed for the categorization of the SLE patients into groups of high, moderate, and weak overexpressers of IFN-α/β-inducible genes. This approach could potentially allow for an accurate assessment of drug target neutralization in early trials of anti-IFN-α mAb therapy for SLE. Furthermore, ex vivo stimulation of healthy donor peripheral blood mononuclear cells with SLE patient serum and subsequent neutralization with anti-IFN-α mAb or anti-IFN-α receptor mAb showed that anti-IFN-α mAb has comparable effects of neutralizing the overexpression of type I IFN-inducible genes as that of anti-IFNAR mAb. These results suggest that IFN-α, and not other members of type I IFN family in SLE patients, is mainly responsible for the induction of type I IFN-inducible genes in WB of SLE patients. Taken together, these data strengthen the view of IFN-α as a therapeutic target for SLE.Keywords
This publication has 26 references indexed in Scilit:
- Evaluation of DNA microarray results with quantitative gene expression platformsNature Biotechnology, 2006
- Association of increased interferon‐inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosusArthritis & Rheumatism, 2006
- Could 2′5′-oligoadenylate synthetase isoforms be biomarkers to differentiate between disease flare and infection in lupus patients? A pilot studyClinical Rheumatology, 2006
- Type I interferon correlates with serological and clinical manifestations of SLEAnnals Of The Rheumatic Diseases, 2005
- The abnormal apoptosis of T cell subsets and possible involvement of IL-10 in systemic lupus erythematosusCellular Immunology, 2005
- IL-10 production in B cells is confined to CD154+ cells in patients with systemic lupus erythematosusJournal of Autoimmunity, 2004
- Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus BloodThe Journal of Experimental Medicine, 2003
- Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupusProceedings of the National Academy of Sciences of the United States of America, 2003
- Neutralizing interferon alpha as a therapeutic approach to autoimmune diseasesCytokine & Growth Factor Reviews, 2003
- Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodiesLupus, 2000